When using the optimum diagnostic cutoff value 50.29 ng/mL, plasma Hsp90α could distinguish breast cancer patients with a sensitivity of 74.41% and a specificity of 71.95% from the non-cancer control (AUC 0.7973; Figure 1E and Table 1). Here, HSP90AA1 is linked to breast carcinoma.